Skip to main content
SpringerLink
Log in

Paliperidone extended release: a guide to its use in schizophrenia

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Yang LPH, Plosker, GL. Paliperidone extended release. CNS Drugs 2007; 21(5): 417–25

    Article  PubMed  CAS  Google Scholar 

  2. European Medicines Agency. Invega 3, 6, 9, or 12 mg: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Nov 16]

  3. Invega™ (paliperidone extended-release tablets): US prescribing information. Titusville (NJ): Janssen, L.P., 2007 Apr

  4. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007 Feb; 90(1): 147–61

    Article  PubMed  CAS  Google Scholar 

  5. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007 Jul; 93(1–3): 117–30

    Article  PubMed  Google Scholar 

  6. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007 Dec 15; 62(12): 1363–70

    Article  PubMed  CAS  Google Scholar 

  7. Tzimos A, Kramer M, Ford L, et al. A six-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients [abstract no. NR441 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON): 183

  8. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extendedrelease tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Feb; 27(1): 6–14

    Article  PubMed  CAS  Google Scholar 

  9. Eerdekens M, Kramer M, Martinez L, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week, open-label extension studies [abstract no. 290]. 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs (CO)

  10. Kramer M, Simpson G, Kushner S, et al. Long-term safety/tolerability of paliperidone extended-release tablets: 52-week, open-label, extension phase of a schizophrenia symptom recurrence prevention study [poster no. 29]. 46th Annual Meeting of the American College of Neuropsychopharmacology; 2007 Dec 9–13; Boca Raton (FL)

  11. Luthringer R, Staner L, Noel N, et al. A double-blind, placebocontrolled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychomarmacol 2007 Sep; 22(5): 229–308

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paliperidone extended release: a guide to its use in schizophrenia. Drugs Ther. Perspect 24, 5–7 (2008). https://doi.org/10.2165/00042310-200824020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824020-00002

Keywords

Search

Navigation